by guest contributor Bonginkosi Shozi, PhD Fellow, African Health Research Flagship, School of Law, University of KwaZulu-Natal
Multilateral Matters
An occasional blog on international developments related to intellectual property, innovation, development and public policy
Preface by Adjunct Professor Wend Wendland
The COVID-19 pandemic has exposed the eggshell fragility of global human health, safety and well-being.
The pandemic is causing severe disruption to societies, economies, supply chains, trade and travel, erasing development gains and devastating the livelihoods of people, especially the poor and most vulnerable.
As a fine dust of anxiety settles over everything we do, never before has the global race for a vaccine, treatment and cure been as urgent.
Once health products of assured quality and safety are developed, global cooperation will be needed to ensure that they will be accessible and affordable to all at the same time.
Availability, accessibility and affordability of health products (such as medicines, vaccines, diagnostic and testing kits, medical devices and protective devices) depend on several factors, such as a country’s manufacturing capacity, the height of trade barriers, the strength of its competition (anti-trust) regulations, the efficiency of procurement procedures, the effectiveness of transportation and delivery mechanisms, and the adequacy of health systems and infrastructure. The pharmaceutical and medical R&D, innovation, production and supply ecosystem is complex.
Intellectual property (IP) rules are relevant too. IP protections may secure the investments needed to produce life-saving innovations, just as they may also hinder competition and constitute a barrier to collaborative innovation and impede access to those innovations. Governments the world over grapple with designing IP systems that incentivize innovation while safeguarding public health.
IP rights are not absolute. They are subject to exceptions and limitations and countries can take advantage of these provisions (also called “flexibilities”) in international instruments to address public health objectives. Further, IP rights don’t apply in all countries: for example, patents apply only in the countries in which they have been applied for and granted. And, under the World Trade Organisation’s (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), least-developed countries need not protect pharmaceuticals until 2033.
More broadly, this extraordinary global threat underscores the critical importance of international solidarity and effective multilateralism. This “Multilateral Matters” blog series shines a beam on the need for and relevance of multilateralism in the IP arena.
For all these reasons I decided that the next “Multilateral Matters” blog post should address the IP/health question, which, with great pleasure, I invited Bonginkosi Shozi, PhD Fellow, African Health Research Flagship, School of Law, University of KwaZulu-Natal, to write under his own responsibility as a guest contributor to “Multilateral Matters”.
While acknowledging the relevance of copyright to access to health-related data and knowledge contained in scientific and medical journals and other literary works, his post specifically addresses the freighted and fraught relationship between patents and health.
This post is also timed to acknowledge “The International Day of Multilateralism and Diplomacy for Peace”, which is celebrated in April each year.[1]
Additional readings will as usual be posted on the Multilateral Matters website.
With my thanks to Bonginkosi, over to him.